Clearly how can you say this is a pump and dump when the FDA looked at the efficacy and agreed with the findings. I hate to say this but how can you possibly in that little mind of yours see this as a pump and dump. You obviously did not listen to the earnings report. They clearly debunked the short report and it did not affect the FDA's decision to grant them the right to continue to use the drug. I think this is just a bonus and the other drugs that are in phase 3 clinical trials are the ones they are hoping for. I would not be surprised if someone comes along and offers a massive buyout.
I am hoping that they continue to squeeze your short balls and close it much higher next week. NO SIDE EFFECTS. This is better than PFIZER and MDNA. They wanted to let you see the side effects in 75 years and no side effects were found with this drug.
Recent VERU News
- Veru to Present at the GLP-1 Based Therapeutics Summit • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:30:37 PM
- Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 • GlobeNewswire Inc. • 04/25/2024 12:30:00 PM
- Veru Announces Date of 2024 Annual Meeting of Shareholders • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- Veru Reschedules Annual Meeting of Shareholders • GlobeNewswire Inc. • 03/22/2024 08:05:00 PM
- Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 02/28/2024 12:15:00 AM
- Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 09:49:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:06:36 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:00:37 PM
- Veru Reports Fiscal 2024 First Quarter Financial Highlights • GlobeNewswire Inc. • 02/08/2024 11:30:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:27:50 PM
- Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 01/31/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:06:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 02:02:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 02:00:32 PM
- Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024 • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/26/2023 09:31:07 PM
- Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 02:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM